Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.40 |
| ▸ | ABL1 | P00519 | 6/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.38 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064141 | 0.89 | NR4A2 (0.67) | NR4A2LRRK2CYP2C9KCNH2WDR5 | |
| SCHEMBL2064586 | 0.83 | NR4A2 (0.58) | NR4A2LRRK2ABL1CYP2C9KCNH2 | |
| SCHEMBL2064088 | 0.83 | NR4A2 (0.61) | NR4A2LRRK2ABL1CYP2C9KCNH2 | |
| SCHEMBL2063098 | 0.81 | NR4A2 (0.63) | NR4A2LRRK2ABL1CYP2C9KCNH2 | |
| SCHEMBL2065198 | 0.81 | NR4A2 (0.63) | NR4A2LRRK2ABL1CYP2C9KCNH2 | |
| SCHEMBL2063498 | 0.81 | NR4A2 (0.61) | NR4A2LRRK2ABL1CYP2C9KCNH2 | |
| SCHEMBL2063551 | 0.80 | NR4A2 (0.77) | NR4A2CYP2C9KCNH2ALDH1A3ALDH1A2 | |
| SCHEMBL2063042 | 0.79 | ALDH1A3 (0.58) | NR4A2LRRK2ABL1CYP2C9KCNH2 | |
| SCHEMBL13269678 | 0.79 | NR4A2 (0.59) | NR4A2LRRK2ABL1CYP2C9KCNH2 | |
| SCHEMBL2064621 | 0.79 | NR4A2 (0.57) | NR4A2LRRK2ABL1CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262803-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-10-17 | — | — | EP | claimed |
| US-8148370-B2 | Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | claimed |
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | claimed |
| EP-2262803-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-10-17 | — | — | EP | disclosed |
| US-8148370-B2 | Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065699-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NR4A2 1531/4885LRRK2 1310/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.